Standards for Tamper-Resistant Painkillers

Despite evidence that tamper-resistant drugs are driving down demand with dealers and users, generic versions of many painkillers are exempt from the course of action the FDA outlines. This has created some controversy among name brand manufacturers, which claim that generics of these drugs should be held to the same standards.
 
The nonprofit group Center for Lawful Access and Abuse Deterrence (CLAAD) agrees; it is asking the FDA to stop crushable generic versions of OxyContin and Opana from reaching pharmacy shelves. A bill that would demand safeguard features on most painkillers is currently in the U.S. House of Representatives, but it is unlikely to pass before the generics are released.